Department of Gynecologic Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan 430071, PR China.
Eur J Surg Oncol. 2010 Feb;36(2):160-3. doi: 10.1016/j.ejso.2009.07.186. Epub 2009 Aug 21.
To identify genetic variants in the E6 gene of HPV 16 and to examine the association between these variants and cervical cancer development.
Cervical samples were collected from 72 patients with cervical cancer and 72 age-matched control subjects, all from Hubei Province, China. HPV 16 sequence was detected with E6 gene-specific polymerase chain reaction, and variants were identified by DNA sequencing.
HPV 16 was detected in 81% of the patients and 43% of control subjects, respectively. The rank orders of incidence of HPV 16 prototype and E6 variants were as follows: D25E (62%), the prototype (17%), E113D (9%), L83V (6%) in case subjects; the prototype (71%), D25E (23%), L83V/E113D (7%) in control subjects. The odds ratio of HPV 16 E6 variant was higher than that of prototype (RR=11.73, 95% CI=4.18-32.94, P=0.0001).
The D25 E variant is the most prevalent E6 genomic variant in Hubei, China. The presence of HPV 16 E6 variant in cervical intraepithelial neoplasia (CIN) lesions may serve as a useful predictor of clinical outcome of the disease.
鉴定 HPV 16 的 E6 基因中的遗传变异，并研究这些变异与宫颈癌发展之间的关系。
采集来自中国湖北省的 72 名宫颈癌患者和 72 名年龄匹配的对照者的宫颈样本。用 E6 基因特异性聚合酶链反应检测 HPV 16 序列，并通过 DNA 测序鉴定变异。
分别在 81%的患者和 43%的对照者中检测到 HPV 16。HPV 16 原型和 E6 变异体的发病顺位如下：病例组中 D25E（62%）、原型（17%）、E113D（9%）、L83V（6%）；对照组中原型（71%）、D25E（23%）、L83V/E113D（7%）。HPV 16 E6 变异体的比值比高于原型（RR=11.73，95%CI=4.18-32.94，P=0.0001）。
D25E 变异是中国湖北最常见的 E6 基因组变异。在宫颈上皮内瘤变（CIN）病变中存在 HPV 16 E6 变异可能是疾病临床结局的有用预测指标。
